Adaptive Biotechnologies (ADPT) Cash & Current Investments (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash & Current Investments across 9 years of filings, most recently posting $344.3 million for Q2 2026.

• In Q2 2026, Cash & Current Investments rose 73.98% year-over-year to $344.3 million; the TTM figure through Jun 2026 stood at $344.3 million (up 73.98% YoY), while the FY2025 annual figure was $227.0 million, up 2.11% from the prior year.
• Cash & Current Investments came in at $344.3 million for Q2 2026 at Adaptive Biotechnologies, up from $218.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $508.1 million in Q3 2022 to a low of $193.4 million in Q1 2025.
• Average Cash & Current Investments over 5 years is $321.6 million, with a median of $326.6 million recorded in 2024.
• Year-over-year, Cash & Current Investments tumbled 49.1% in 2022 and soared 73.98% in 2026.
• Over 5 years, Cash & Current Investments stood at $498.2 million in 2022, then sank by 30.47% to $346.4 million in 2023, then plunged by 35.83% to $222.3 million in 2024, then increased by 2.11% to $227.0 million in 2025, then soared by 51.67% to $344.3 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $344.3 million in Q2 2026, $218.3 million in Q1 2026, and $227.0 million in Q4 2025.